Evidence map›Paper›PMID 29233947›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2017

Reply to Mohlin et al.: High levels of

Isabelle Westerlund, Yao Shi, Konstantinos Toskas, Stuart M Fell, Shuijie Li, Erik Södersten, Susanne Schlisio, Johan Holmberg

Abstract readLetterComment
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. HIF2α negatively regulates MYCN protein levels and promotes a low-risk noradrenergic phenotype in neuroblastoma.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Isabelle WesterlundDepartment of Cell and Molecular Biology, Ludwig Institute for Cancer Research, Karolinska Institutet, 171 77 Stockholm, Sweden.
Yao ShiDepartment of Cell and Molecular Biology, Ludwig Institute for Cancer Research, Karolinska Institutet, 171 77 Stockholm, Sweden.
Konstantinos ToskasDepartment of Cell and Molecular Biology, Ludwig Institute for Cancer Research, Karolinska Institutet, 171 77 Stockholm, Sweden.
Stuart M FellDepartment of Cell and Molecular Biology, Ludwig Institute for Cancer Research, Karolinska Institutet, 171 77 Stockholm, Sweden.
Shuijie LiDepartment of Cell and Molecular Biology, Ludwig Institute for Cancer Research, Karolinska Institutet, 171 77 Stockholm, Sweden.
Erik SöderstenDepartment of Cell and Molecular Biology, Ludwig Institute for Cancer Research, Karolinska Institutet, 171 77 Stockholm, Sweden.
Susanne SchlisioDepartment of Cell and Molecular Biology, Ludwig Institute for Cancer Research, Karolinska Institutet, 171 77 Stockholm, Sweden.
Johan HolmbergDepartment of Cell and Molecular Biology, Ludwig Institute for Cancer Research, Karolinska Institutet, 171 77 Stockholm, Sweden; johan.holmberg@ki.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Basic Helix-Loop-Helix ProteinsNeuroblastomaHumansBasic Helix-Loop-Helix Proteins

Identifiers

PMID29233947
PMCPMC5754814

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.